Home » Newsletters » BioWorld Science

BioWorld Science

July 2, 2003

View Archived Issues

Enrollment completed in phase II trial of SRP-299 for asthma

Thai phase IIa trial of DB-289 for malaria opens enrollment

Acapodene reduces high-grade prostate intraepithelial neoplasia in phase II study

Lexicon Genetics discover new target for cognitive disorders

Positive Japanese phase III data for Zadaxin in hepatitis B

Cypress Bioscience prepares for milnacipran trial in IBS

Phase I results for NBI-42902

Schering acquires license to Philogen's antibody-based therapeutic fusion protein

Manufacturing begins in preparation for EradicAide trial

Oxazole-based inducers of BDNF production and their use in diabetic neuropathy

New aciclovir prodrugs and their use in ocular viral infections

Roche researchers describe the preparation and use of novel cathepsin K inhibitors

New CRF antagonists in early development at Roche

Novel glucagon antagonists in Novo Nordisk development pipeline

Novartis patents new mGluR5 antagonists for anxiety, pain, etc.

Metabolic glutamate mGluR5 antagonists covered by Merck patent

New thrombin inhibitors prepared and tested by U. of Ljubljana and LEK researchers

Inhibition of alpha4beta1 as a new approach to multiple sclerosis

In vitro and in vivo profile of new orally active histamine H3 antagonist

CPMP hands down positive opinion for Avandamet

Clenoliximab enhances the efficacy of methotrexate in active rheumatoid arthritis

Comparison of the efficacy and safety profiles of etoricoxib and naproxen in rheumatoid arthritis

Inspire files first NDA for ocular therapy partnered with Allergan

Phase III ARISE trial of AGI-1067 opens enrollment

ABthrax cleared to enter clinical testing

Bexxar approved by FDA

Beneficial effects of pregabalin in healthy volunteers and patients with fibromyalgia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...